Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41047 CHAIN BRIDGE I (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdict ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | --- | |----------------------------------------------------------------------------|--------------------------------------------|------ ...

NEW YORK and SANTA BARBARA, Calif., July 30, 2024 – Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoidlike molecules, today announced the release of its new investor deck. The updated presentation provides an indepth look at the company's strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. Key Highlights of the Inves ...

NEW YORK and SANTA BARBARA, Calif., July 30, 2024 – Phytanix Bio, a pioneering preclinical stage pharmaceutical company dedicated to the development of therapeutics based on cannabinoid and cannabinoidlike molecules, today announced the release of its new investor deck. The updated presentation provides an indepth look at the company's strategic vision, scientific advancements, and growth potential as it progresses towards the development of next-generation cannabinoid medicines. Strategic Vision and Missio ...

Phytanix Bio is a preclinical stage pharmaceutical company founded by former members and associates of GW Pharmaceuticals, holding exclusive cannabinoid and cannabinoid-like medicine intellectual property (IP) The transaction reflects a pre-deal valuation of $58 million for Phytanix Bio plus the assumption of $17 million of preferred stock and $4.4 million of short-term debt that will be exchanged for convertible preferred stock at deal close The business combination is expected to be completed in the fourt ...

Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|------------------------------- ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41047 Registrant's telephone number, including area code: (302) 597-7438 Securities registered pursuant to Section 12(b) of the Act: TABLE OF CONTENTS Item 6. [Reserved] 60 Item 7. Management's Discussion and Analysis of Finan ...

Table of Contents CHAIN BRIDGE I (Exact name of registrant as specified in its charter) Cayman Islands 95-1578955 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Burlingame, California (Address of principal executive offices) 94010 (ZipCode) Not Applicable (Former name or former address, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Table of Contents Table of Contents Table of Contents PART I. FINANCIAL INFORM ...

Cautionary Note Regarding Forward-Looking Statements Internal Control over Financial Reporting The underwriters were entitled to an underwriting discount of $0.20 per Unit, or approximately $4.6 million in the aggregate, paid upon the closing of the Initial Public Offering. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 10th day of August, 2023. Table of Contents | ...

| --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------|---------------|---------------------------------------|------------|----------------------------------------------|-------|-------------------------------------------------------| | Description \nAssets: | Quoted Active | Prices in Markets (Level 1) | Observable | Significant Other Inputs (Level 2) | | Significant Other Unobservable Inputs (Level 3) | | (1) Investments held in T ...